Friedreich ataxia is a rare, inherited, neurodegenerative disorder that affects the nervous system, resulting in progressive physical and cognitive disability. It is estimated to affect approximately 1 in 50,000 people worldwide. It is caused by a mutation in a gene called FXN, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia. This article will provide an overview of Friedreich ataxia, including its causes, symptoms, diagnosis, and treatments.
Friedreich ataxia is an inherited disorder that affects the nervous system and causes progressive physical and cognitive disability. It is caused by a mutation in the FXN gene, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia.
The symptoms of Friedreich ataxia vary from person to person, but usually appear in childhood or adolescence. Common symptoms include: • Progressive loss of coordination, balance, and muscle strength • Loss of sensation in the extremities • Slurred speech and difficulty swallowing • Vision problems • Hearing loss • Heart problems • Fatigue • Scoliosis • Diabetes
Friedreich ataxia is caused by a mutation in the FXN gene, which is responsible for producing a protein called frataxin. Frataxin is essential for healthy cell function in the body, and when it is missing, cells cannot perform their normal functions, leading to the symptoms of Friedreich ataxia.
Friedreich ataxia is usually diagnosed through a combination of physical examination, neurological testing, and genetic testing. Physical examination may reveal signs of muscle weakness, coordination problems, and scoliosis. Neurological testing may reveal impaired reflexes, muscle weakness, and balance problems. Genetic testing can confirm the presence of the FXN gene mutation.
There is currently no cure for Friedreich ataxia, but there are treatments available to help manage the symptoms. Treatment may include physical therapy, occupational therapy, speech therapy, and medications to help manage pain, fatigue, and other symptoms. Additionally, there are clinical trials underway to investigate potential treatments for Friedreich ataxia.
Friedreich ataxia is a rare, inherited, neurodegenerative disorder that affects the nervous system, resulting in progressive physical and cognitive disability. It is caused by a mutation in a gene called FXN, which is responsible for producing a protein called frataxin. Diagnosis involves physical examination, neurological testing, and genetic testing, and treatments may include physical therapy, occupational therapy, speech therapy, and medications. While there is currently no cure for Friedreich ataxia, there are treatments available to help manage the symptoms and clinical trials underway to investigate potential treatments.
1.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
2.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
3.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
3.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation